

Differential Chemokine Alteration in the Variants of Primary Progressive Aphasia – A Role for Neuroinflammation

Aitana Sogorb Esteve

University College London Dementia Research Centre <https://orcid.org/0000-0002-7869-8192>

Imogen J. Swift

University College London Dementia Research Centre

Ione O.C. Woollacott

University College London Dementia Research Centre

Jason D. Warren

University College London

Henrik Zetterberg

Goteborgs universitet Sahlgrenska Akademin

Jonathan D. Rohrer (✉ j.rohrer@ucl.ac.uk)

University College London Dementia Research Centre <https://orcid.org/0000-0002-6155-8417>

Research

Keywords: frontotemporal dementia, primary progressive aphasia, chemokines

Posted Date: April 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-386614/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

The primary progressive aphasia (PPA) represent a group of usually sporadic neurodegenerative disorders with three main variants: the nonfluent or agrammatic variant (nfvPPA), the semantic variant (svPPA), and the logopenic variant (lvPPA). They are usually associated with a specific underlying pathology: nfvPPA with a primary tauopathy, svPPA with a TDP-43 proteinopathy, and lvPPA with underlying Alzheimer's disease (AD). Little is known about their cause or pathophysiology but prior studies in both AD and svPPA have suggested a role for neuroinflammation. In this study we set out to investigate the role of chemokines across the PPA spectrum, with a primary focus on central changes in cerebrospinal fluid (CSF)

Methods

36 participants with sporadic PPA (11 svPPA, 13 nfvPPA and 12 lvPPA) as well as 19 healthy controls were recruited to the study and donated CSF and plasma samples. All patients with lvPPA had a tau/A β 42 biomarker profile consistent with AD, whilst this was normal in the other PPA groups and controls. We assessed twenty chemokines in CSF and plasma using Proximity Extension Assay technology: CCL2 (MCP-1), CCL3 (MIP-1a), CCL4 (MIP-1 β), CCL7 (MCP-3), CCL8 (MCP-2), CCL11 (eotaxin), CCL13 (MCP-4), CCL19, CCL20, CCL23, CCL25, CCL28, CX3CL1 (fractalkine), CXCL1, CXCL5, CXCL6, CXCL8 (IL-8), CXCL9, CXCL10, and CXCL11.

Results

In CSF, CCL19 and CXCL6 were decreased in both svPPA and nfvPPA compared with controls whilst CXCL5, was decreased in the nfvPPA group with a borderline significant decrease in the svPPA group. In contrast, CCL2, CCL3 and CX3CL1 were increased in lvPPA compared with controls and nfvPPA (and greater than svPPA for CX3CL1). CXCL1 was also increased in lvPPA compared with nfvPPA but not the other groups. CX3CL1 was significantly correlated with CSF total tau concentrations in the controls and each of the PPA groups. Fewer significant differences were seen between groups in plasma, although in general, results were in the opposite direction to CSF i.e. decreased in lvPPA compared with controls (CCL3 and CCL19), and increased in svPPA (CCL8) and nfvPPA (CCL13).

Conclusion

Differential alteration of chemokines across the PPA variants is seen in both CSF and plasma. Importantly, these results suggest a role for neuroinflammation in these poorly understood sporadic disorders, and therefore also a potential future therapeutic target.

Background

The primary progressive aphasia (PPA) are a rare group of disorders characterised by focal degeneration of the brain regions involved in language function (1), and fall within the frontotemporal dementia (FTD) spectrum. There are three main variants - the nonfluent or agrammatic variant (nfvPPA), the semantic variant (svPPA), and the logopenic variant (lvPPA) - distinguished by the language deficits with which they present as well as their neuroanatomical signatures (2). Similarly, the predominant neuropathology underlying each of the variants usually differs, with nfvPPA most commonly a tauopathy such as progressive supranuclear palsy or corticobasal degeneration (3, 4), whilst svPPA is almost always a TDP-43 proteinopathy (5). In contrast lvPPA is not a frontotemporal lobar degeneration (FTLD) pathologically (i.e. not a primary tauopathy or TDP-43 proteinopathy) in most cases (6); instead, the underlying pathology is usually that of Alzheimer's disease (AD), and lvPPA is often therefore considered an atypical language variant of AD.

Recent studies have shown that neuroinflammation is an important pathophysiological factor in neurodegenerative disorders (7). Although less research has been performed in FTD, molecular, pathological and biomarker studies all suggest that inflammation is important here as well (reviewed in Bright et al(8)). The process of neuroinflammation is complex and multistage but involves activation of glial cells, which in turn leads to upregulation of several proteins that help to guide the response. These include chemokines, a family of proteins that regulate leukocyte traffic but also have a number of other roles both within the immune system and outside, e.g. in development and synaptic transmission (9). Only a few studies have so far investigated changes in chemokines in FTD spectrum disorders (9,10 and reviewed in Swift et al. 11), and so we aimed to assess this more thoroughly by using a panel of chemokines in the biofluids of a well-defined cohort of people from across the PPA spectrum, particularly focusing on changes centrally within the cerebrospinal fluid (CSF).

Methods

Participants

Thirty-six people with sporadic PPA and available CSF and plasma were consecutively recruited through the Longitudinal Investigation of FTD (LIFTD) study at University College London: 11 svPPA, 13 nfvPPA, and 12 lvPPA(2). All cases were negative for a C9orf72 expansion and mutations in any of the genes causative of FTD. 19 healthy controls were recruited over the same time period. All patients with lvPPA had a biomarker profile consistent with underlying Alzheimer's disease: mean (standard deviation) total tau/A β 42 ratio (INNOTEST®, Fujirebio Europe N.V., Gent, Belgium) of 3.2 (2.2) with a range 1.2 to 8.3 where > 1 is considered abnormal. All svPPA or nfvPPA participants and all controls had a ratio < 1.

Proximity Extension Assay panel

Twenty chemokines were measured in the CSF and plasma of all participants using Proximity Extension Assay technology on the Olink® inflammatory panel (13). Briefly, samples were incubated with matched

antibodies with DNA tags. When matched antibodies come in close proximity, DNA tags will only hybridise when the coupled antibodies match and then the sequence is amplified by qPCR. Results are expressed as normalized protein expression values. The chemokines measured were CCL2 (MCP-1), CCL3 (MIP-1a), CCL4 (MIP-1 β), CCL7 (MCP-3), CCL8 (MCP-2), CCL11 (eotaxin), CCL13 (MCP-4), CCL19, CCL20, CCL23, CCL25, CCL28, CX3CL1 (fractalkine), CXCL1, CXCL5, CXCL6, CXCL8 (IL-8), CXCL9, CXCL10, and CXCL11.

Statistical analysis

All statistical analyses were performed in STATA (v.16)) with the primary analysis focused on the results in the CSF. The Shapiro-Wilk test was performed to determine the normality of distribution of each chemokine measure in each group. The levels of each chemokine in the CSF were compared between groups using a linear regression model; bootstrapping with 1000 repetitions was used if the chemokine measures were not normal. Spearman correlation coefficients were assessed for each individual chemokine between their values and each of A β 42 and total tau (t-tau) concentrations within the control and PPA groups.

In order to explore the relationship between chemokine values in CSF and plasma, Spearman correlation coefficients were assessed in each individual chemokine between CSF and plasma values within the control group as well as the disease groups.

The levels of each chemokine in the plasma were subsequently compared between groups using a linear regression model as previously; bootstrapping with 1000 repetitions was used if the chemokine measures were not normal.

Results

There were no significant differences between the group in terms of either age at sampling or sex: mean (standard deviation) age in controls 63.5 (6.9), percentage male 47%; svPPA 60.5 (5.9), 54.5; nfvPPA 67.0 (6.3), 53.8; lvPPA 66.7 (6.9), 50.0.

Within CSF, three chemokines had > 80% of values across the groups below the lower limit of detection (CCL20 44/55, CCL13 53/55, CCL7 54/55) and were not assessed further. Seven of the remaining 17 chemokines showed a significant difference between groups. In both svPPA and nfvPPA, CCL19 and CXCL6 were decreased compared with controls (Figure, Supplementary Table 1): CCL19 – mean (standard deviation) controls 8.4 (1.1), svPPA 7.1 (1.5), nfvPPA 7.6 (1.1), lvPPA 8.5 (0.6); CXCL6 – controls 3.1 (0.7), svPPA 2.5 (0.7), nfvPPA 2.5 (0.9), lvPPA 3.1 (0.7). CCL19 was additionally significantly decreased in both nfvPPA and svPPA compared with lvPPA, as was CXCL5, although this chemokine was decreased only in the nfvPPA group compared with controls (albeit with a borderline significant decrease in the svPPA group): controls 3.3 (0.5), svPPA 2.9 (0.4), nfvPPA 2.8 (0.8), lvPPA 3.4 (0.6). In contrast, CCL2, CCL3 and CX3CL1 were increased in lvPPA compared with controls (and greater than nfvPPA for CCL2, and both nfvPPA and svPPA for CX3CL1): CCL2 – controls 11.2 (0.4), svPPA 11.3 (0.5), nfvPPA

11.2 (0.3), lvPPA 11.6 (0.6); CCL3 – controls 2.5 (0.3), svPPA 2.5 (0.4), nfvPPA 2.5 (0.4), lvPPA 2.8 (0.4); CX3CL1 – controls 3.5 (0.4), svPPA 3.4 (0.3), nfvPPA 3.3 (0.5), lvPPA 3.8 (0.4). CXCL1 was also increased in lvPPA compared with nfvPPA but not the other groups: controls 5.9 (0.5), svPPA 5.9 (0.4), nfvPPA 5.7 (0.8), lvPPA 6.2 (0.5).

No correlations were found between A β 42 concentrations and values of any of the chemokines within the controls or the PPA groups except for a correlation in the nfvPPA group for CXCL6: rho = 0.58, p = 0.033. However, CX3CL1 was significantly correlated with t-tau concentrations in the controls and each of the PPA groups: controls rho = 0.51, p = 0.025, svPPA rho = 0.64, p = 0.035, nfvPPA rho = 0.72, p = 0.005, lvPPA rho = 0.59, p = 0.045. None of the other chemokines correlated with t-tau across the groups but CCL4 was correlated in controls (rho = 0.59, p = 0.033), and CXCL5 was correlated in svPPA (rho = 0.65, p = 0.029).

In the chemokines that were found to be abnormal in CSF across groups, none of the CSF values were correlated with plasma values within the control group or any of the PPA groups. Only chemokines for which no significant group differences were seen showed a correlation between CSF and plasma values, both within the control group (CCL8: rho = 0.48, p = 0.039; CCL11: rho = 0.46; p = 0.048; CCL25: rho = 0.53, p = 0.021), the lvPPA group (CCL4: rho = 0.68, p = 0.015; CXCL8: rho = 0.79; p = 0.002), and the nfvPPA group (CCL4: rho = 0.78, p = 0.002; CCL11: rho = 0.64; p = 0.017; CCL25: rho = 0.58, p = 0.040; CXCL10: rho = 0.66, p = 0.014). No correlations were seen in the svPPA group.

Within plasma, fewer significant differences were seen between groups (Supplementary Fig. 1, Supplementary Table 2). However, CCL8 was higher in svPPA compared with controls and CCL13 was higher (with CCL20 lower) in nfvPPA compared with controls: CCL8 - controls 8.3 (1.1), svPPA 9.1 (0.6), nfvPPA 8.7 (1.0), lvPPA 8.7 (0.5); CCL13 - controls 4.0 (1.5), svPPA 4.4 (1.1), nfvPPA 5.0 (1.4), lvPPA 5.0 (1.2); CCL20 - controls 5.7 (1.0), svPPA 5.3 (0.8), nfvPPA 5.0 (0.8), lvPPA 5.4 (0.7). In contrast, CCL3 and CCL19 were significantly lower in lvPPA compared with controls and the svPPA group (as well as the nfvPPA group for CCL3): CCL3 - controls 3.8 (1.1), svPPA 4.0 (1.3), nfvPPA 3.6 (0.4), lvPPA 3.2 (0.3); CCL19 - controls 10.2 (1.1), svPPA 10.1 (1.1), nfvPPA 9.8 (1.3), lvPPA 9.2 (0.5). Additionally, CCL4 was lower in lvPPA compared with nfvPPA but not with the other groups: controls 7.3 (1.0), svPPA 7.4 (1.2), nfvPPA 7.4 (0.8), lvPPA 6.9 (0.4).

Discussion

We report chemokine levels in biofluids in PPA, showing differential alteration across the PPA variants. Interestingly, the direction of significant change differed between those with underlying AD pathologically (lvPPA, where CSF values were increased and plasma values decreased) and those with FTLD (svPPA and nfvPPA, where CSF values were decreased, and for all but one chemokine, plasma values were increased). Comparing the CSF chemokine values with CSF biomarkers of amyloid and tau, CX3CL1, which was increased in lvPPA, was significantly correlated with t-tau concentrations across all of the groups.

In keeping with lvPPA being associated with underlying AD pathology, the findings of increased CCL2, CCL3 and CX3CL1 in this group parallel previous studies in those with a typical AD clinical presentation (10–24). CCL2 (MCP-1) is expressed by neurons, astrocytes and microglia, and has previously been shown to be raised in the CSF of people with typical AD including those with mild cognitive impairment (MCI) (14–16). A further study also showed that CSF CCL2 concentrations correlated with the extent of brain atrophy and cognitive impairment in AD (17), with one report suggesting that higher levels were associated with more rapid progression from MCI to AD (18). CCL3 (MIP-1a) is also expressed by neurons, astrocytes and microglia (19), and this expression has been shown to be increased in the brains of people with AD as well as in mouse models (20, 21). Here we show increased levels of CCL3 in the CSF of the atypical AD phenotype lvPPA. Interestingly we also show lower levels of CCL3 peripherally in the plasma, a finding also previously found by another group in serum (22). Lastly, CX3CL1 (fractalkine) is produced by neurons, particularly in the hippocampus and cortex, and suppresses microglial activation. Importantly, from an AD perspective, CX3CL1 has also been shown to be upregulated in the hippocampus during memory-associated synaptic plasticity (23). Several studies have demonstrated significantly higher CSF concentrations of CX3CL1 in people with MCI and AD (20), with concentration being shown to differentiate MCI from controls with high sensitivity and specificity (24). Our study also showed a strong correlation with t-tau in lvPPA as well as in the controls and other groups, suggesting an association with increased neuronal damage particularly in the AD brain.

Although non-significant, a number of other chemokines showed a trend to an increase in lvPPA compared with controls e.g. CCL23 ($p = 0.068$), increased concentrations of which have previously been shown to help predict progression from MCI to AD (25). CXCL1 showed a significant increase in lvPPA compared with nvPPA; this chemokine has also been shown to be increased in the CSF of people with AD in a prior study (26).

Overall, this study highlights the important pathophysiological overlap of atypical variants of AD with the more typical variant. Here we show that the central chemokine profile of change is similar in lvPPA to that found in amnesic AD.

In contrast, the two FTLN pathological forms of PPA show differential alterations of chemokines to lvPPA, with parallel decreases in CCL19, CXCL5 and CXCL6 in both svPPA and nvPPA. This finding suggests that these are related to underlying FTLN pathology per se, rather than the individual proteinopathy, as svPPA (TDP-43) and nvPPA (tau) usually differ in their primary pathological cause. Unfortunately, little is known about alterations in chemokines levels in FTD so far. Only a few small studies have investigated chemokines, showing decreased levels of CCL5 (RANTES) and increased levels of CCL2, CXCL8 and CXCL10 in CSF (8)(10). Previous studies have not investigated such an extensive set of chemokines in FTD across differential pathologies. CCL19, CXCL5 and CXCL6 are all expressed in the brain, although their roles are not clear. Nonetheless, CCL19 in particular has been studied in neuroinflammation-related diseases such as multiple sclerosis (27, 28), although here the levels were increased rather than decreased as found in our study. Whilst these are preliminary findings in nvPPA and svPPA, they are important in signalling a role for neuroinflammation in these disorders. Little is

currently known about why these sporadic diseases develop, and although a few studies have previously suggested a role for neuroinflammation in svPPA (29, 30), this study also suggests it is a relevant pathophysiological phenomenon in nfvPPA also.

Whilst central neuroinflammatory processes in neurodegenerative disorders are increasingly well-studied, fewer studies have investigated peripheral immune findings. There was generally poor correlation between CSF chemokine values and those in plasma within the controls, suggesting that peripheral values generally do not represent central levels. However, abnormal values were found in each of the PPA variants compared with controls (and for all but one measure, in the opposite direction to that found centrally in CSF). Certainly for svPPA a previous study has showed an increase in systemic autoimmune disease compared with controls (30), but otherwise little is known about peripheral inflammation in PPA, and more studies are required.

Conclusions

Overall, this study shows highlights the complex inflammatory response in the different variants of PPA and shows clear differences between those with AD and FTLD pathology. Our results establish a baseline for further study of the role of chemokines in PPA with the potential role of neuroinflammation as a therapeutic target in these sporadic disorders an important area of future research.

List Of Abbreviations

PPA
Primary progressive aphasia
FTD
Frontotemporal dementia
nfvPPA
Nonfluent/agrammatic variant PPA
svPPA
Semantic variant PPA
lvPPA
Logopenic variant PPA
FTLD
Frontotemporal lobar degeneration
TDP-43
TAR DNA-binding protein 43
AD
Alzheimer's disease
CSF
Cerebrospinal fluid
C9orf72

Chromosome 9 open reading frame 72

qPCR

quantitative Polymerase Chain Reaction

CCL2 (MCP-1)

C-C motif chemokine 2 (Monocyte chemoattractant protein 1)

CCL3 (MIP-1a)

C-C motif chemokine 3 (Macrophage inflammatory protein 1 alpha)

CCL4 (MIP-1 β)

C-C motif chemokine 4 (Macrophage inflammatory protein 1 beta)

CCL7 (MCP-3)

C-C motif chemokine 7 (Monocyte chemoattractant protein 3)

CCL8 (MCP-2)

C-C motif chemokine 8 (Monocyte chemoattractant protein 2)

CCL11

Eotaxin

CCL13 (MCP-4)

C-C motif chemokine 13 (Monocyte chemoattractant protein 4)

CCL19

C-C motif chemokine 19

CCL20

C-C motif chemokine 20

CCL23

C-C motif chemokine 23

CCL25

C-C motif chemokine 25

CCL28

C-C motif chemokine 28

CX3CL1

Fractalkine

CXCL1

Growth-regulated alpha protein

CXCL5

C-X-C motif chemokine 5

CXCL6

C-X-C motif chemokine 6

CXCL8 (IL-8)

Interleukin 8

CXCL9

C-X-C motif chemokine 9

CXCL10

C-X-C motif chemokine 10
CXCL11
C-X-C motif chemokine 11
MCI
Mild cognitive impairment

Declarations

Ethics approval

The London Queen Square Ethics committee approved the study.

Consent for publication

All participants provided written informed consent at enrolment including consent to publication.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

HZ has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. JDR has served on medical advisory boards and consultancy for Alector, Arkuda Therapeutics, Wave Life Sciences, and Prevail Therapeutics. Consultancy for UCB, AC Immune, Astex Pharmaceuticals, Biogen, Takeda and Eisai.

Funding

The Dementia Research Centre is supported by Alzheimer's Research UK, Alzheimer's Society, Brain Research UK, and The Wolfson Foundation. This work was supported by the NIHR UCL/H Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility, and the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. ASE is supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. IJS is supported by the Alzheimer's Association. IOCW was supported by an MRC Clinical Research Training Fellowship (MR/M018288/1). JDW receives funding support from the Alzheimer's Society, Alzheimer's Research UK and NIHR UCLH Biomedical Research Centre. HZ is a Wallenberg Scholar supported by grants from the Swedish Research

Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. JDR has received funding from an MRC Clinician Scientist Fellowship (MR/M008525/1) and an NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH); his work is also supported by the MRC UK GENFI grant (MR/M023664/1), the Bluefield Project and the JPND GENFI-PROX grant (2019-02248).

Authors' contributions

ASE and JDR analysed and interpreted the data and wrote the initial draft of the manuscript. IOCW and ISJ collected and processed the samples from participants. All authors read and approved the final manuscript.

Acknowledgements

We thank the research participants for their contribution to the study.

References

1. Marshall CR, Hardy CJD, Volkmer A, Russell LL, Bond RL, Fletcher PD, et al. Primary progressive aphasia: a clinical approach. *J Neurol*. 2018 Jun 1;265(6):1474–90.
2. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011 Mar 15;76(11):1006–14.
3. Graff-Radford J, Duffy JR, Strand EA, Josephs KA. Parkinsonian motor features distinguish the agrammatic from logopenic variant of primary progressive aphasia. *Park Relat Disord*. 2012 Aug;18(7):890–2. 6/
4. Kremen SA, Mendez MF, Tsai PH, Teng E. Extrapyrmidal Signs in the Primary Progressive Aphasias. *Am J Alzheimers Dis Other Demen*. 2011;26(1):72–7.
5. Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Vol. 6, *Lancet Neurology*. Lancet Neurol; 2007. p. 1004–14.
6. Henry ML, Gorno-Tempini ML. The logopenic variant of primary progressive aphasia. Vol. 23, *Current Opinion in Neurology*. Curr Opin Neurol; 2010. p. 633–7.
7. Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). *Mol Med Rep*. 2016 Apr 1;13(4):3391–6.
8. Bright F, Werry EL, Dobson-Stone C, Piguet O, Ittner LM, Halliday GM, et al. Neuroinflammation in frontotemporal dementia. *Nat Rev Neurol*. 2019;15(9):540–55.

9. Miller RJ, Rostene W, Apartis E, Banisadr G, Biber K, Milligan ED, et al. Chemokine action in the nervous system. In: *Journal of Neuroscience*. *J Neurosci*; 2008. p. 11792–5.
10. Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi SMG, Fumagalli G, et al. Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. *Brain Behav Immun*. 2015;49:182–7.
11. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, et al. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. *J Neurol*. 2008;255(4):539–44.
12. Swift IJ, Sogorb-Esteve A, Heller C, Synofzik M, Otto M, Graff C, et al. Fluid biomarkers in frontotemporal dementia: Past, present and future. *Journal of Neurology, Neurosurgery and Psychiatry*. BMJ Publishing Group; 2020. 2021 Feb;92(2):204-215.
13. Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PLoS One*. 2014 Apr 22;9(4).
14. Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer's disease continuum. *J Neuroinflammation*. 2019 Feb 21;16(1).
15. Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, et al. Inflammatory markers in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review of 170 studies. *J Neurol Neurosurg Psychiatry*. 2019 May 1;90(5):590–8.
16. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease. *Arch Neurol*. 2006 Apr 1;63(4):538.
17. Kimura A, Yoshikura N, Hayashi Y, Inuzuka T. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease. *J Alzheimer's Dis*. 2017;61(2):581–8.
18. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. *PLoS One*. 2012 Jan 30;7(1).
19. Xia M, Qin S, Wu L, Mackay CR, Hyman BT. Immunohistochemical study of the β -chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. *Am J Pathol*. 1998;153(1):31–7.
20. Azizi G, Khannazer N, Mirshafiey A. The potential role of chemokines in alzheimer's disease pathogenesis. Vol. 29, *American Journal of Alzheimer's Disease and other Dementias*. SAGE Publications Inc.; 2014. p. 415–25.
21. Martin E, Boucher C, Fontaine B, Delarasse C. Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer's disease models: effects of aging and amyloid pathology. *Aging Cell*. 2017 Feb 1;16(1):27–38.

22. Geppert AM, Losy J, Przedpelska-Ober E, Kozubski W. CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer's disease. *Psychiatry Res.* 2010 Apr;176(2–3):261–4.
23. Sheridan GK, Wdowicz A, Pickering M, Watters O, Halley P, O'Sullivan NC, et al. CX3CL1 is up-regulated in the rat hippocampus during memory-associated synaptic plasticity. *Front Cell Neurosci.* 2014 Aug 12;8(AUG).
24. Kulczyńska-Przybik A, Słowik A, Mroczo P, Borawski B, Groblewska M, Borawska R, et al. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. *Curr Alzheimer Res.* 2020 Nov 9;17.
25. Faura J, Bustamante A, Penalba A, Giralt D, Simats A, Martínez-Sáez E, et al. CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. *J Alzheimer's Dis.* 2020;73(4):1585–95.
26. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis. Bush AI, editor. *PLoS One.* 2011 Apr 19;6(4):e18850.
27. Krumbholz M, Theil D, Steinmeyer F, Cepok S, Hemmer B, Hofbauer M, et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. *J Neuroimmunol.* 2007 Oct;190(1–2):72–9.
28. Lepennetier G, Hracsko Z, Unger M, Van Griensven M, Grummel V, Krumbholz M, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. *J Neuroinflammation.* 2019 Nov 14;16(1).
29. Heller C, Chan E, Foiani MS, Todd E, Russell LL, Greaves C V, et al. Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. *J Neurol Neurosurg Psychiatry.* 2020 Nov 20;jnnp-2020-325085.
30. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. *J Neurol Neurosurg Psychiatry.* 2013;84(9):956–62.

Figures




Figure 1

Mean normalized protein expression values for the chemokines in controls and each of PPA groups in CSF. Significant differences with p values are shown on the graphs.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementalFigure1plasma.pdf](#)
- [SupplementaryTables.docx](#)